🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Interesting stuff here! Includes my pitch for rare dz platform studies —>

100% agree.

Interesting idea —>

Good news for those of us in this neck of the woods!

Classic “platform biotech” problem. Most of the value creation is very far downstream — but that requires additional skills/capabilities/resources that the platform co usually doesn’t have — and those parts are hard!

How to detect BS in biotech PR — useful airplane reading if you’re heading to JPM. pharmagellan.com/blog/red-flags…

Seems interesting (with caveat that I don’t follow this area closely) —>

These are banger ideas — can’t wait to read these stories!

When I started my blog > 1 yr ago, I was super worried it would hurt my career prospects. Not only did that not happen, the exact opposite is true. I think the vibe shift helped, but it's something I couldn't have known back then.

This x1000 in biopharma R&D. HT Alexander Berger

Good study of how market incentives spur biopharma innovation. HT Alexander Berger

Interesting project, doc, and thread on anti-aging clinical trial design. I’m happy to have made a small contribution and looking forward to seeing how these ideas develop!

+1 to this — STAT’s meeting space at JPM is awesome! Thanks so much for setting it up.

I'm very humbled and excited to announce a career change come summertime. Thanks to all at Case Western for a wonderful and productive 18+ years. nationaljewish.org/about-us/news/…

Really great interview w/Jack Scannell about biopharma R&D. I have minor quibbles w/ his thoughts on how feasible it is to improve preclinical models, but nonetheless excellent. overcast.fm/+ABM7oddQ-bM

Example of interpreting announced delay of an event-driven clinical trial —>

Several of my Tufts bio students have raved about Eitan Hersh, so I sat in the back one day last term to see for myself. The hype is well-deserved. Students were riveted and engaged. Lots of food for thought for me as a newbie teacher.

Big loss for Stat, huge get for Bloomberg — and massive congrats to you, Rachel Cohrs Zhang! You’ve been a force of nature on the DC biopharma beat and I’m sure you’ll continue to do fab work.